To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 121 participants.

Also called NCT05908084

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05908084
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05908084. Randomized; single masking; primary purpose treatment. Start 2023-09-07 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Condition
End Stage Renal Disease (ESRD)
Intervention (Biological)
Acellular Tissue Engineered Vessel (ATEV)
Intervention (Other)
AVF
Lead sponsor
Humacyte, Inc. (class: industry)
Collaborator
IQVIA Biotech (class: industry)

Record details

Record id
cardio:ct-nct05908084
Content hash
b02f191bea93f7ad3c16133f71dd4bbb63c2e5bf119a8e5d442da29eacc19adc